18.11.2010

MagForce Nanotechnologies AG to Present at Deutsches Eigenkapitalforum

Berlin, November 18, 2010- MagForce Nanotechnologies AG (FSE:MF6), a leader in the area of nanotechnology-based cancer treatment, announced today that Dr. Peter Heinrich, CEO, will present the latest company developments and outline plans for 2011 at the Deutsches Eigenkapitalforum. The presentation will take place on Tuesday, November 23, 2010, at 8:15 in Sector Technology (Paris Room). Earlier this year, MagForce received EU approval for its medical products, NanoTherm® and NanoActivatorTM, for the treatment of brain tumors. The company plans to launch its Nano-Cancer® therapy at leading cancer centers in Germany in the first quarter of 2011.


 

ABOUT MAGFORCE NANOTECHNOLOGIES:

MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. The proprietary procedure which it has developed, Nano-Cancer® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm® and NanoActivator®, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.

DISCLAIMER:

This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.

 

17.11.2010

MagForce Selected as Winner of 2010 STEP Award in the Category Product/Technology

  • Prize awarded in recognition of company’s innovation and growth potential

Berlin, November 17, 2010 - MagForce Nanotechnologies AG (FSE:MF6), a leader in the area of nanotechnology-based cancer treatment, announced today that it has been selected as the 2010 recipient of the STEP award in the category product/technology. The business award, initiated by Infraserv Höchst and F.A.Z. Institute along with leading industry sponsors, was awarded for the fifth time this year.

“We are honored to receive the prestigious STEP award in recognition of MagForce’s novel therapy for the treatment of brain tumors. Our innovative therapeutic approach uses nanoparticles, which are activated through the application of a magnetic field to produce heat within the tumor,” said Dr. Peter Heinrich, CEO of MagForce. “Following our recent EU approval, we are focusing on building the commercial structures needed to launch of our Nano-Cancer® therapy at leading German cancer centers in early 2011. Our transformation from a research and development company to a commercial business also signifies a new therapy option for patients diagnosed with brain tumors.”

More than 100 companies competed in this year’s STEP award. Small and mid-sized growth companies in innovative fields ranging from pharmaceuticals, chemicals, life science, biotechnology, and nanotechnology to medical and green technology are eligible to take part in the annual competition.


 

ABOUT MAGFORCE NANOTECHNOLOGIES:

MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. The proprietary procedure which it has developed, Nano-Cancer® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm® and NanoActivator®, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.

DISCLAIMER:

This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.

 

15.11.2010

MagForce Nanotechnologies AG Announces Management Team Expansion

  • Key positions expand internal corporate structures and support Q1 2011 Nano-Cancer® therapy product launch
  • Additional commercialization positions to be filled in the coming weeks

Berlin, November 15, 2010 - MagForce Nanotechnologies AG (FSE:MF6), a leader in the area of nanotechnology-based cancer treatment, announced today the expansion of its management team.  The new positions, Director of Intellectual Property, Director of Business/Corporate Development, Director of Finance & Controlling, and Director of Investor Relations & Corporate Communications, will support both the upcoming product launch of the company’s EU approved therapy for the treatment of brain tumors and the further development of its Nano-Cancer® therapy in additional cancer indications. MagForce expects its Nano-Cancer® therapy will become available at several leading German cancer centers in the first quarter of 2011.

“Filling these key company positions is an important step in the transformation of the company from a research and development only business into a commercial company. Additional hiring for the sales and marketing team will be completed by the end of the year,” said Dr. Peter Heinrich, CEO of MagForce. “I am extremely pleased to welcome Dr. Christoph Rehfuess, Dr. Dirk Kautz, Mr. Kajo Wiest, and Ms. Stacy Wiedenmann to MagForce.  Furthermore, Dr. Hans Joachim Hutt is currently serving as a medical consultant. These individuals bring with them the experience and expertise to support MagForce as we build commercial infrastructures and medical networks.”

Dr. Christoph Rehfuess joins MagForce as Director of Intellectual Property. As a qualified European patent attorney with twelve years of management experience in the biotech intellectual property field at Medigene AG, he will be responsible for patents, trademarks, and technical contracts.

Dr. Dirk Kautz joins MagForce as Director of Business/Corporate Development and will support the Management Board in strategic planning. Prior to joining MagForce, he worked for more than 13 years in the medical devices industry, holding management positions in marketing and corporate development at, among others, Nihon Kohden and Biotronik.

Kajo Wiest joins as Director of Finance & Controlling and brings with him more than 10 years of finance and controlling experience at Jerini AG. During his time at Jerini, he was responsible for the establishment of controlling structures as well as supporting the company’s IPO and the sale of its wholly-owned subsidiary JPT, where he served as Finance Manager last year.

Stacy Wiedenmann joins the company as Director of Investor Relations & Corporate Communications and brings with her over 10 years of experience, including her experience at Jerini AG, where she headed the same areas from their IPO through their acquisition.

Dr. Hans Joachim Hutt MD, PhD will support the company in the area of Medical Affairs.  His medical training and over 20 years of experience at leading pharmaceutical companies, including Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Sanofi Pasteur MSD, will help MagForce establish commercial networks and expand its therapeutic applications.


 

ABOUT MAGFORCE NANOTECHNOLOGIES:

MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. The proprietary procedure which it has developed, Nano-Cancer® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm® and NanoActivator®, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.

DISCLAIMER:

This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.

 

21.09.2010

MagForce Nanotechnologies AG Announces Publication of Clinical Data Using Nanoparticles for the Treatment of Recurrent Glioblastoma Multiforme

Berlin, September 21, 2010- MagForce Nanotechnologies AG (FSE:MF6) announced today the publication of clinical data from a clinical study examining the safety and efficacy of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy in patients with recurrent glioblastoma multiforme.

The study data, published on September 20, 2010 in the Journal of Neuro-Oncology, is available online on the Journal’s website at www.springerlink.com/content/u27ll42612302123/ or www.ncbi.nlm.nih.gov/pubmed/20845061
"This data publication provides detailed insight into the clinical data that supported our recent regulatory approval for Nano-Cancer® therapy. Through the publication, we are pleased to address a wider international audience and give them insight into MagForce’s novel concept of using nanotechnology for the treatment of cancer," said Dr. Peter Heinrich, CEO of MagForce Nanotechnologies AG. "We are currently focused on strengthening our commercialization team and infrastructures in preparation for the next strategic steps, including the planned Q1 2011 product launch in Germany, additional clinical trials, and further internationalization.”
Nano-Cancer® therapy uses iron oxide nanoparticles, which are injected into the tumor and, due to their special coating, aggregate and remain in place.  The patient is then placed into a magnetic field applicator. Through the application of an alternating magnetic field, the nanoparticles begin to oscillate, produce warmth, and damage or kill the tumor tissue.


 

ABOUT MAGFORCE NANOTECHNOLOGIES:

MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. The proprietary procedure which it has developed, Nano-Cancer® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm® and NanoActivator®, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.

DISCLAIMER:

This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.